KROS - Keros Therapeutics, Inc.

QQQ $ 451.45 $ -1.25 (-0.28 %)

DIA $ 399.76 $ 0.64 (0.16 %)

SPY $ 529.26 $ 0.18 (0.03 %)

TLT $ 91.40 $ -0.22 (-0.24 %)

GLD $ 223.63 $ 1.39 (0.63 %)

Previous Close

$ 53.99

Open

$ 54.00

Bid

$ 51.89 x 101

Ask

$ 0.00 x 0

Day's Range

$ 51.85 - $ 54.29

52 Week Range

$ 27.02 - $ 73.00

Volume

195,013

Average Volume

Market Cap

1.93B

Beta (5Y Monthly)

$ 0.92

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	05-08-2024	03-31-2024	10-Q
2	02-28-2024	12-31-2023	10-K
3	11-06-2023	09-30-2023	10-Q
4	08-07-2023	06-30-2023	10-Q
5	05-04-2023	03-31-2023	10-Q
6	03-03-2023	12-31-2022	10-K
7	11-03-2022	09-30-2022	10-Q
8	08-04-2022	06-30-2022	10-Q
9	05-05-2022	03-31-2022	10-Q
10	03-09-2022	12-31-2021	10-K
11	11-04-2021	09-30-2021	10-Q
12	08-05-2021	06-30-2021	10-Q
13	05-06-2021	03-31-2021	10-Q
14	03-25-2021	12-31-2020	10-K
15	11-10-2020	09-30-2020	10-Q
16	08-13-2020	06-30-2020	10-Q
17	05-22-2020	03-31-2020	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

HC Wainwright & Co. Reiterates Buy on Kero...
05/09/2024 11:56:38

HC Wainwright & Co. analyst Andrew Fein reiterates Keros Therapeutics (NASDAQ:KROS) with a Buy and maintains $100 price ...

Keros Therapeutics Q1 EPS $(1.21) Beats $(...
05/08/2024 12:29:56

Keros Therapeutics (NASDAQ:KROS) reported quarterly losses of $(1.21) per share which beat the analyst consensus estimate of $(...

Piper Sandler Maintains Overweight on Kero...
03/27/2024 16:48:15

Piper Sandler analyst Joseph Catanzaro maintains Keros Therapeutics (NASDAQ:KROS) with a Overweight and maintains $105 price...

Keros Therapeutics Announces FDA Fast Trac...
03/14/2024 12:03:17

Truist Securities Reiterates Buy on Keros ...
03/13/2024 17:23:37

Truist Securities analyst Srikripa Devarakonda reiterates Keros Therapeutics (NASDAQ:KROS) with a Buy and maintains $100 pri...

HC Wainwright & Co. Reiterates Buy on Kero...
03/01/2024 11:40:44

HC Wainwright & Co. analyst Andrew Fein reiterates Keros Therapeutics (NASDAQ:KROS) with a Buy and maintains $100 price ...

Keros Therapeutics Q4 EPS $(1.34) Beats $(...
02/28/2024 21:33:21

Keros Therapeutics (NASDAQ:KROS) reported quarterly losses of $(1.34) per share which beat the analyst consensus estimate of $(...

why-mobileye-global-shares-are-trading-lower-by-over-23-here-are-other-stocks-moving-in-thursdays-mid-day-session

Why Mobileye Global Shares Are Trading Low...
01/04/2024 18:37:44

Shares of Mobileye Global Inc. (NASDAQ: MBLY) fell sharply during Thursday’s session after the company issued preliminary FY23...

Lamb Weston Posts Upbeat Results, Joins Om...
01/04/2024 15:12:36

U.S. stocks traded mostly higher, with the Dow Jones index gaining around 150 points on Thursday. Shares of Lamb Weston Holdin...

Keros Therapeutics Prices Upsized $140M Pu...
01/04/2024 07:01:56

Keros Therapeutics Announces Proposed $120...
01/03/2024 21:06:29

Keros Therapeutics Announces Plans To Deve...
01/03/2024 13:05:19

why-bluebird-bio-shares-are-trading-higher-here-are-other-stocks-moving-in-mondays-mid-day-session

Why bluebird bio Shares Are Trading Higher...
12/11/2023 18:12:59

Shares of bluebird bio, Inc. (NASDAQ: BLUE) rose sharply during Monday’s session after the company presented updated data from ...

Coinbase, Riot Platforms, Marathon Digital...
12/11/2023 16:07:21

U.S. stocks traded mostly mixed, with the Dow Jones index gaining more than 100 points on Monday. Here are some other big stoc...

Keros Therapeutics Showcases Phase 2 Trial...
12/11/2023 11:02:41

Keros Therapeutics, Inc. ("Keros") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and ...

Wells Fargo Initiates Coverage On Keros Th...
12/08/2023 18:35:20

Wells Fargo analyst Tiago Fauth initiates coverage on Keros Therapeutics (NASDAQ:KROS) with a Overweight rating and announce...

Wedbush Reiterates Outperform on Keros The...
11/13/2023 14:02:12

Wedbush analyst Andreas Argyrides reiterates Keros Therapeutics (NASDAQ:KROS) with a Outperform and maintains $86 price target.

Keros Therapeutics Q3 EPS $(1.33) Beats $(...
11/06/2023 13:10:05

Keros Therapeutics (NASDAQ:KROS) reported quarterly losses of $(1.33) per share which beat the analyst consensus estimate of $(...

Stocks That Hit 52-Week Lows On Wednesday
10/04/2023 16:01:17

On Wednesday, 311 stocks hit new 52-week lows.

Keros Therapeutics Presents Preclinical Da...
10/04/2023 12:20:07

Keros Therapeutics, Inc. ("Keros") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and ...